RenovoRx Total Liabilities 2020-2024 | RNXT

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

RenovoRx total liabilities from 2020 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

RenovoRx total liabilities from 2020 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$146.3B
Gilead Sciences (GILD)	$114.5B
Bristol Myers Squibb (BMY)	$114.2B
Vertex Pharmaceuticals (VRTX)	$108.7B
CSL (CSLLY)	$83.4B
Regeneron Pharmaceuticals (REGN)	$74.9B
GSK (GSK)	$69.3B
Argenex SE (ARGX)	$38.7B
Alnylam Pharmaceuticals (ALNY)	$31.8B
BioNTech SE (BNTX)	$26.8B
Illumina (ILMN)	$21.7B
BeiGene (ONC)	$20.5B
Biogen (BIIB)	$20.5B
Incyte (INCY)	$13.9B
Genmab (GMAB)	$13.8B
Genmab (GNMSF)	$13.7B
Intra-Cellular Therapies (ITCI)	$13.4B
Moderna (MRNA)	$13.1B
Insmed (INSM)	$13B
Bio-Techne Corp (TECH)	$12B
BioMarin Pharmaceutical (BMRN)	$11.7B
Sarepta Therapeutics (SRPT)	$11.3B
Vaxcyte (PCVX)	$10.6B
QIAGEN (QGEN)	$10.5B
Exelixis (EXEL)	$10.3B
Swedish Orphan Biovitrum (BIOVF)	$10.1B
Exact Sciences (EXAS)	$9.6B
Bio-Rad Laboratories (BIO.B)	$9.5B
Repligen (RGEN)	$9B
Roivant Sciences (ROIV)	$8.1B